AOD-9604
Also known as: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
Buy in shop
AOD-9604 from $81/kit
3 verified vendors, ≥99% purity, COAs included.
Key Facts: AOD-9604
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Clinical trials completed - Did not achieve FDA approval. Removed from FDA Category 2 Sept 2024; expected reclassification to Category 1 (April 15, 2026 HHS announcement; PCAC review July 23-24, 2026). Has GRAS status.
- Administration
- Subcutaneous injection or oral (studied both)
- Typical Dose
- 300 mcg daily
- Frequency
- Once daily, usually morning fasted
- Duration
- 12-24 weeks in studies
Mechanism of Action
AOD-9604 mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. It stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells.
Research Summary
Clinical trials showed modest weight loss effects but failed to meet primary endpoints for FDA approval. Some studies show cartilage regeneration potential. Research demonstrates safety profile similar to placebo with no significant GH-like side effects.
Dosing Information
Typical Dosingⓘ
Community experience
300 mcg daily
250-500 mcg daily
Once daily, usually morning fasted
HGH fragment for fat loss. Take on empty stomach. Often combined with fasted cardio for enhanced fat burning.
Research Dosingⓘ
Scientific studies
Doses from clinical trials
Doses from Studies
250-500 mcg daily
Clinical trials used 1mg oral daily
Duration
12-24 weeks in studies
Administration
Subcutaneous injection or oral (studied both)
Timing & Administration
Best Time to Take
Morning (fasted)
Once daily, 30 min before breakfast
Food Recommendation
Take on empty stomach
Why This Timing?
AOD-9604 works on fat metabolism. Fasted morning use may enhance fat-burning effects.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally very well-tolerated
- ●Injection site reactions
- ●Mild headache
- ●Dizziness
- ●Does NOT produce typical HGH side effects
- ●No effect on IGF-1 levels
- ●GRAS status by expert panel
References
- https://pubmed.ncbi.nlm.nih.gov/11713213/
- https://pubmed.ncbi.nlm.nih.gov/11673763/
- https://pubmed.ncbi.nlm.nih.gov/11146367/
Research This Peptide Further
Buy in shop
AOD-9604 from $81/kit
3 verified vendors, ≥99% purity, COAs included.
Frequently Asked Questions
What does AOD-9604 do?
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
How does AOD-9604 work?
AOD-9604 mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. It stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells.
Is AOD-9604 FDA approved?
No, AOD-9604 is not currently FDA approved. Current status: Clinical trials completed - Did not achieve FDA approval. Removed from FDA Category 2 Sept 2024; expected reclassification to Category 1 (April 15, 2026 HHS announcement; PCAC review July 23-24, 2026). Has GRAS status.
What are the side effects of AOD-9604?
Reported side effects include: Generally very well-tolerated, Injection site reactions, Mild headache, Dizziness, Does NOT produce typical HGH side effects. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of AOD-9604?
Community-reported common dose: 300 mcg daily (Once daily, usually morning fasted). Range: 250-500 mcg daily. Administration: Subcutaneous injection or oral (studied both). Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with AOD-9604 or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Weight LossOrforglipron
FDAAn oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Weight LossCagriSema
Clinical TrialsA combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Weight LossHGH Fragment 176-191
Clinical TrialsThe lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
Weight LossWant updates on AOD-9604 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.